HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease
Adler J, Galanko J, Ammoury R, Benkov K, Bousvaros A, Boyle B, Cabrera J, Chun K, Dorsey J, Ebach D, Firestine A, Gulati A, Herfarth H, Jester T, Kaplan J, Leibowitz I, Linville T, Margolis P, Minar P, Molle-Rios Z, Moses J, Olano K, Pashankar D, Pitch L, Saeed S, Samson C, Sandberg K, Steiner S, Strople J, Sullivan J, Wali P, Kappelman M. HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease. The American Journal Of Gastroenterology 2024, 120: 1076-1086. PMID: 39423015, DOI: 10.14309/ajg.0000000000003135.Peer-Reviewed Original ResearchHLA-DQA1*05Anti-drug antibodiesDQA1*05Anti-drug antibody developmentTreatment failureCrohn's diseaseAnti-TNFPositive patientsDevelopment of anti-drug antibodiesAnti-TNF treatment failureTumor necrosis factor antagonistsIndicator of treatment failureAnti-TNF monotherapyPediatric Crohn's diseaseIncreased treatment failureTrial of childrenYears of ageRandomized trial of childrenOral methotrexatePositive participantsRisk stratificationPediatric dataRandomized trialsIncreased riskPrimary outcome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply